Kava: Traditional Use, Constituents and Evidence

Somewhere around 3,000 years ago, communities across the Pacific islands began preparing a drink from the roots of Piper methysticum that would become one of the most culturally embedded plant preparations on earth. Kava keeps coming up in conversation, partly because of the wave of kava bars opening in Australian cities, partly because the TGA's position on it has shifted in measurable ways. It's one of those plants that sits at an interesting crossroads: deep traditional use and context, a reasonably well-characterised phytochemistry, and a research base that is genuinely promising in some areas and genuinely cautionary in others.

Worth working through properly, I think.

Traditional use and cultural context

Kava's ceremonial use spans Vanuatu, Fiji, Tonga, Samoa, Hawaii and much of Micronesia. The preparation method has remained largely consistent across millennia: the root and rhizome of P. methysticum are ground or pounded, mixed with water, strained, and consumed collectively. In many communities, the ceremony surrounding preparation and sharing is as significant as the drink itself. Kava circles in Vanuatu, for instance, follow strict conventions around who pours, who drinks first, and how the space is held. It would be a mistake to flatten that history into a simple "traditional herbal remedy" label, because the cultural architecture around it is sophisticated.

European contact records from the late 18th century, including accounts from members of Captain Cook's voyages, noted kava's effects with curiosity (and a fair amount of caution). The German pharmacologist Ludwig Lewin published the first rigorous chemical investigation in 1886, isolating what he called "kavahin", later identified as the kavalactone fraction. That marks the beginning of the modern phytochemical story. For general background on the plant itself, see the Wikipedia entry on kava.

Key constituents: the kavalactones

The pharmacologically active fraction of kava root is dominated by a group of compounds collectively called kavalactones (also known as kavapyrones). Around 18 have been identified, but six account for the vast majority of activity in most root preparations: kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin. The relative ratios of these six compounds vary considerably between kava chemotypes, a point that becomes very relevant when discussing both efficacy data and safety signals.

The chemotype of the plant matters enormously. Noble kava varieties, traditionally selected and cultivated across generations, have a distinct kavalactone profile that differs meaningfully from so-called "tudei" (two-day) varieties, which are associated with higher levels of flavokavains and dihydromethysticin, and with stronger adverse effect profiles. A lot of the hepatotoxicity cases reported in the early 2000s, which prompted bans in several European countries, have since been attributed partly to the use of aerial plant parts (leaves and stems rather than root), non-noble chemotypes, or concentrated ethanolic extracts rather than traditional aqueous preparations. This is not a settled scientific question, but it's the current weight of opinion in the published literature.

Kava preparations sold or listed in Australia should ideally be prepared from noble varieties using the root only, though regulatory requirements around this are not uniformly enforced at the product level. If you're researching standardised extracts, keep in mind that "standardised to kavalactones" tells you very little about chemotype or which specific kavalactones are present.

Proposed mechanisms of action

This is where it gets genuinely interesting from a phytomedicine perspective. Kavalactones don't behave like a single-target molecule; their pharmacological profile is diffuse and not entirely mapped. Several mechanisms have been proposed:

• GABA-A receptor modulation: Multiple kavalactones, particularly kavain and dihydrokavain, appear to potentiate GABA-A receptor activity in a manner somewhat distinct from benzodiazepines, acting on binding sites that differ from the classical benzodiazepine site. This is one of the more consistently replicated findings in in vitro research.
• Sodium and calcium channel inhibition: Dihydromethysticin and kavain have shown inhibitory effects on voltage-gated sodium and calcium channels in preclinical models, which some researchers associate with the muscle-relaxant quality described in traditional use.
• Monoamine reuptake: Some kavalactones appear to weakly inhibit reuptake of noradrenaline and dopamine in animal models, though the clinical significance of this is unclear.
• Endocannabinoid system interactions: Yangonin has been identified as a ligand with affinity for CB1 receptors, which sits within the broader endocannabinoid system. This is an area of early research only, and the functional significance at physiologically relevant concentrations is not yet established.

The pharmacokinetics of kavalactones are reasonably well documented in human volunteer studies. Kavain reaches peak plasma concentration within roughly one hour of oral consumption of an aqueous extract, with a half-life of approximately 90 minutes. Fat-soluble kavalactones show different absorption profiles; another reason the traditional water-based preparation and modern lipid-extracted concentrated products may behave differently in the body.

Readers comparing botanicals with a long traditional history may also find the library's articles on valerian traditional use and passionflower traditional use useful, as the same questions about preparation and evidence quality apply.

The evidence base: what research actually shows (and its limits)

I'll be direct here: the clinical evidence on kava is more rigorous than for most botanicals, but it still has significant limitations.

Several randomised controlled trials, including a 2003 Cochrane review updated in subsequent years, examined aqueous kava extracts against placebo. The pooled findings suggested statistically significant effects on validated anxiety rating scales, but the trials were generally small, short in duration (4–8 weeks), and methodologically heterogeneous. A 2013 double-blind RCT published in the Journal of Clinical Psychopharmacology by Sarris et al. found significant effects on generalised anxiety symptoms using a water-soluble kava extract compared with placebo, with a reasonable safety profile over eight weeks. But, and this is the bit that often gets left out, the effect sizes were modest, the sample was small (75 participants), and longer-term data are essentially absent.

Ongoing research from groups at the University of Melbourne has continued to look at aqueous preparations specifically, partly as a response to the hepatotoxicity questions that dominated the literature in the 2000s. That hepatotoxicity signal is real but appears to be dose-dependent, preparation-dependent, and heavily influenced by chemotype. The European bans were largely lifted after safety reviews, including an assessment by the WHO, that concluded noble-variety aqueous kava root preparations carry substantially lower hepatic risk than the solvent-extracted products that drove the original reports.

None of this constitutes evidence that kava treats any condition. The research describes pharmacological effects and observed outcomes in controlled settings. It doesn't translate directly to clinical recommendation.

Australian regulation: import controls and TGA listing

This is the part that surprises people. Kava has a genuinely complicated regulatory history in Australia, quite separate from its listing as a phytomedicine.

For many years, kava importation into Australia was subject to strict controls, including a 2-kg personal importation limit, primarily under a policy framework designed to address harm in some Northern Territory and remote Indigenous communities where problematic use patterns had been documented. That framework has evolved. As of late 2021, the Australian Government lifted the 2-kg import restriction for personal use of kava as a food product, and Fiji was named as the initial approved country of commercial origin, with commercial importation permitted under new food standards. The change was specifically framed in terms of supporting Pacific trade relationships while maintaining safety oversight. Kava remains subject to biosecurity screening and import conditions under the Biosecurity Act 2015.

For listed medicines (not food products), the TGA governs kava through the ARTG. Complementary medicine products containing kava can be listed (ARTG Listed, "AUST L") if they meet specified safety and quality criteria, but the TGA has applied specific conditions: products must use noble kava root only, kavalactone daily dose limits apply, and labelling must carry liver-health warnings. The listed medicine pathway does not permit therapeutic claims beyond those allowed under the complementary medicine framework. Kava is not currently approved as a registered medicine for any indication in Australia.

Honestly, I think the food/medicine boundary around kava is one of the more awkward regulatory lines the TGA and FSANZ have had to draw. The same plant preparation sits in different frameworks depending almost entirely on how it's presented and marketed, which creates some odd gaps.

Preparations, quality and what to look for

Traditional preparation (aqueous, from noble-variety dried root) is the most studied and, on current evidence, the preparation with the most favourable safety profile. The kavalactone content of commercial products varies widely; a 2019 analysis of products available in Australian and US markets found significant inconsistencies between labelled and actual kavalactone content.

For listed medicines, Good Manufacturing Practice requirements apply under the TGA framework, which provides some quality assurance. For kava sold as a food product (e.g. dried root for traditional preparation), those requirements don't apply in the same way.

If you're reading research papers on kava and trying to interpret them, pay attention to: the chemotype used, whether the extract is aqueous or solvent-based, the dose expressed as total kavalactones and individual constituent ratios, and study duration. Two studies using "kava extract" may be studying quite different things.

Kava is a plant that demands careful attention to source and preparation, much as any traditional botanical does. The phytochemistry is interesting. The history is rich. The research has real momentum. But the gaps are gaps, and they're worth naming.

Sources

• Kava, Australian Regulatory Guidelines for Complementary Medicines, TGA (Therapeutic Goods Administration)
• Sarris J et al. (2013), "Kava in the Treatment of Generalized Anxiety Disorder"; NCBI/PubMed
• Assessment of the Risk of Hepatotoxicity with Kava Products, World Health Organization
• Kava Drug Facts, Alcohol and Drug Foundation (ADF)

Naomi Ellison, Botanical & phytomedicine writer